Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004583-26
    Sponsor's Protocol Code Number:LV2020-001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-06-09
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-004583-26
    A.3Full title of the trial
    A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD1d-positive chronic lymphocytic leukemia, multiple
    myeloma or acute myeloid leukemia
    Uno studio di fase 1 e 2a in aperto volto a valutare la sicurezza, la tollerabilità, la farmacocinetica, la farmacodinamica, l’immunogenicità e l’attività antitumorale di LAVA-051 in pazienti affetti da leucemia linfocitica cronica, mieloma multiplo o leucemia mieloide acuta recidivanti o refrattari positivi a CD1d.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia
    Uno studio volto a valutare la sicurezza e la tollerabilità del nuovo prodotto sperimentale LAVA-051 in pazienti affetti da leucemia linfocitica cronica, mieloma multiplo o leucemia mieloide acuta non responsivi o recidivanti.
    A.3.2Name or abbreviated title of the trial where available
    LAVA
    LAVA
    A.4.1Sponsor's protocol code numberLV2020-001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLAVA Therapeutics NV
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLAVA Therapeutics B.V.
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCATO SMS
    B.5.2Functional name of contact pointProject Manager
    B.5.3 Address:
    B.5.3.1Street AddressStationsplein NO 438
    B.5.3.2Town/ citySchiphol
    B.5.3.3Post code1117 CL
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31204350580
    B.5.5Fax number+31204350589
    B.5.6E-mailSSUReg@cato-sms.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLAVA-051
    D.3.2Product code [LAVA-051]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeLAVA-051
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    CD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)
    LLC, MM o LMA recidivanti/refrattari positivi a CD1d
    E.1.1.1Medical condition in easily understood language
    Patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia
    Pazienti con LLC, MM o LMA
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part 1 Dose Escalation
    • To investigate the safety and tolerability of LAVA-051 in patients with relapsed/refractory CLL, MM, or AML with positive tumor cell expression for CD1d.
    • To determine the recommended Phase 2a dose (RP2D) of LAVA-051 in patients with relapsed/refractory CLL, MM or AML with positive tumor cell expression for CD1d.
    Part 2 Proof of Concept (PoC)
    • To evaluate the antitumor activity of LAVA-051 at the respective RP2D in separate cohorts with relapsed/refractory CLL, MM or AML with positive tumor cell expression for CD1d.
    • To investigate the safety and tolerability of LAVA-051 in these respective expansion cohorts.
    Parte 1, Incremento progressivo della dose
    • Indagare la sicurezza e tollerabilità di LAVA-051 nei pazienti affetti da LLC, MM o LMA recidivanti/refrattari e con cellule tumorali esprimenti CD1d.
    • Determinare la RP2D di LAVA-051 per i pazienti affetti da LLC, MM o LMA recidivanti/refrattari e con cellule tumorali esprimenti CD1d.
    Parte 2, PoC
    • Valutare l’attività antitumorale di LAVA-051 alle rispettive RP2D nelle singole coorti di pazienti affetti da LLC, MM o LMA recidivanti/refrattari e con cellule tumorali esprimenti CD1d.
    • Indagare la sicurezza e tollerabilità di LAVA-051 nelle rispettive coorti di espansione.
    E.2.2Secondary objectives of the trial
    Part 1 Dose Escalation
    • To explore the antitumor activity of LAVA-051.
    Part 1 Dose Escalation and Part 2 PoC
    • To evaluate the pharmacokinetics of LAVA-051.
    • To evaluate the pharmacodynamics of LAVA-051.
    • To evaluate the immunogenicity of LAVA-051.
    Obiettivi secondari:
    Parte 1, Incremento progressivo della dose
    • Esaminare l’attività antitumorale di LAVA-051.
    Parte 1, Incremento progressivo della dose e Parte 2, PoC
    • Valutare la farmacocinetica di LAVA-051.
    • Valutare la farmacodinamica di LAVA-051.
    • Valutare l’immunogenicità di LAVA-051.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Patient must be 18 years of age inclusive or above, at the time of signing the informed consent
    2. Confirmed tumor cell CD1d positivity/expression
    3. Patients with documented diagnosis of CLL, MM, or AML who have failed to respond to or who have relapsed after prior therapy and are not amenable to standard treatments or for whom no standard treatments are available. Patients may have undergone prior cell therapy
    CLL/ SL) patients:
    -Proven disease by the presence of CD5+CD19+CD23+ clonal B cells in blood, bone marrow and/or lymph nodes.
    -Patients should meet criteria for requiring therapy (the most recent iwCLL guidelines (39)) and must have measurable disease (measurable lesion > 1.5 cm diameter in at least one dimension) and/or lymphocytosis
    -Patients must have failed at least one line of targeted therapy (ibrutinib or venetoclax or similar) and not be amenable to- or for whom no further standard treatment is available
    -Patients with Richter’s transformation can be included in Part 1 of the trial but not in Part 2 of the trial
    MM patients:
    -Documented diagnosis of MM and measurable disease
    -Documented progression or refractory multiple myeloma as per the IMWG uniform response criteria following =3 prior regimens that include at least one immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody in any order.
    AML patients:
    -Patients with relapsed/refractory AML
    -Patients with relapsed/refractory AML after at least one prior AML therapy.
    4. Males or non-pregnant, non-breastfeeding females who are:
    a. Surgically sterile
    b. Female of childbearing potential with a negative pregnancy test prior to first dosing and compliant with a highly effective contraceptive regimen from signing of the ICF through 90 days after the last IMP administration. Abstinence is not considered an adequate contraceptive regimen.
    c. Female, postmenopausal defined as continuous amenorrhea for at least 12 consecutive months without an alternative medical cause and a serum follicle-stimulating hormone (FSH) measurement of > 40 IU/L).
    d. Male, compliant with an effective contraceptive regimen (i.e., use of male condom with female partner and assuring use of an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant following from signing of the ICF through 90 days after the last IMP administration; refer to Appendix 4, Section 13.4 for more details) from signing of the ICF through 90 days after the last IMP administration). Abstinence is not considered an adequate contraceptive regimen.
    e. Male, refraining from donating sperm following from signing of the ICF through 90 days after the last IMP administration.
    5. Predicted life-expectancy of = 3 months
    6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    7. Adequate renal function (estimated glomerular filtration rate [eGFR] per local laboratory > 40 mL/min/1.73m2), hepatic function [(total bilirubin = 2 times upper limit of normal (ULN), unless in patients with known Gilbert’s syndrome who must have total bilirubin = 3 times ULN; AST and ALT = 3.0 times ULN] and hematological function (neutrophils = 1 x109/L; platelet count = 75x109/L, unless due to bone marrow tumor infiltration, in which case it must be = 50x109/L)
    8. Capable of giving signed and dated informed consent prior to initiation of any trial-related procedure that is not considered Standard of Care which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
    1. Età pari o superiore a 18 anni al momento della firma del consenso informato.
    2. Confermata positività/espressione di CD1d sulle cellule tumorali. Nota: i pazienti verranno sottoposti a prescreening per verificare che le cellule tumorali esprimano CD1d.
    3. Diagnosi documentata di LLC, MM o LMA che non risponde al trattamento oppure che risulta recidivante dopo precedente terapia e non sensibile ai trattamenti standard oppure per il/la quale non esistono trattamenti standard. I pazienti possono essere stati sottoposti in precedenza a una terapia cellulare.
    a. Per i pazienti affetti da LLC/SLL:
    –Diagnosi della malattia dimostrata dalla presenza nel sangue, nel midollo osseo e/o nei linfonodi di espansione clonale di linfociti B CD5+, CD19+, CD23+. È possibile includere i pazienti con trasformazione di Richter nella Parte 1 dello studio, ma non nella successiva Parte 2.
    –I pazienti devono soddisfare i criteri previsti per la terapia necessaria e la loro malattia deve essere misurabile (il diametro di una lesione misurabile è > 1,5 cm su almeno una dimensione) e/o devono presentare linfocitosi.
    –I pazienti devono non aver risposto ad almeno una linea di terapia a bersaglio molecolare, non devono essere sensibili al trattamento standard oppure non devono esistere ulteriori trattamenti standard per la loro condizione.
    b. Per i pazienti affetti da MM:
    –Diagnosi documentata di MM e malattia misurabile
    –Progressione documentata o refrattarietà del MM, sulla base dei criteri uniformi di risposta dell’IMWG, a seguito di = 3 regimi di trattamento precedenti che includevano, non necessariamente nel seguente ordine, almeno un farmaco immunomodulatore, un inibitore del proteasoma e un anticorpo monoclonale anti-CD38.
    c. Per i pazienti affetti da LMA:
    –LMA recidivante/refrattaria. Ciò include qualsiasi tipo di LMA, ad esclusione della leucemia promielocitica acuta (LPA, LMA-M3).
    – LMA recidivante/refrattaria a seguito di almeno una terapia precedente per LMA.
    4. I pazienti di sesso maschile oppure le pazienti di sesso femminile, che non sono in stato di gravidanza e che non allattano al seno, devono soddisfare i seguenti criteri:
    a. Essere stati sottoposti a sterilizzazione chirurgica
    b. Per le pazienti di sesso femminile potenzialmente fertili: test di gravidanza, effettuato precedentemente alla prima somministrazione, con esito negativo. Inoltre, tali pazienti devono adottare un metodo contraccettivo altamente efficace. Tali metodi contraccettivi devono essere adottati dal momento della firma del ICF e per un periodo di 90 giorni successivo all’ultima somministrazione dell’IMP. L’astinenza non è considerata un metodo contraccettivo adeguato.
    c. Pazienti di sesso femminile in postmenopausa, definita tale quando il periodo di amenorrea continua dura da almeno 12 mesi consecutivi, senza che ci siano altre cause mediche, e il valore del FSH nel siero è > 40 IU/L.
    d. Per i pazienti di sesso maschile: impiego di un metodo contraccettivo efficace. Tali metodi contraccettivi devono essere utilizzati dal momento della firma dell’ICF e per un periodo di 90 giorni successivo all’ultima somministrazione dell’IMP. L’astinenza non è considerata un metodo contraccettivo adeguato.
    e. Pazienti di sesso maschile che non doneranno sperma dal momento della firma dell’ICF e per un periodo di 90 giorni successivo all’ultima somministrazione dell’IMP.
    5. Aspettativa di vita prevista = 3 mesi.
    6. Stato di validità di 0 o 1 sulla scala ECOG
    7. Funzione renale adeguata, funzione epatica adeguata e funzione ematologica adeguata
    8. I pazienti devono essere in grado di fornire il modulo di consenso informato firmato e datato prima dell’avvio di qualsiasi procedura legata allo studio, che non sia considerata parte dello Standard di cura, compresa la conformità ai requisiti e alle limitazioni elencate nell’ICF e nel protocollo
    E.4Principal exclusion criteria
    1. Prior allogeneic bone marrow transplant as long as the patient still has active acute or chronic graft versus host disease requiring >10 mg prednisone or equivalent corticosteroids.
    2. Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma. Patients who had no evidence of disease from another primary cancer for 2 or more years are allowed to participate in the trial. Localized non-metastatic prostate cancer, not requiring systemic treatment, and for which no local treatment is planned, is allowed.
    3. Uncontrolled or severe intercurrent medical condition.
    4. Known uncontrolled central nervous system involvement.
    5. Patient has any active-, uncontrolled-, or suspected infection.
    6. A significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this trial.
    7. Unstable cardiovascular function defined as: (a) symptomatic ischemia, or (b) uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic agents are excluded; 1st degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block (left anterior fascicular block /right bundle branch block) will not be excluded), or (c) congestive heart failure New York Heart Association Class = 3, or (d) myocardial infarction within 3 months.
    8. Previous treatment with radiotherapy, immunotherapy, or chemotherapy in the 2 weeks prior to initial IMP administration.
    9. Previous treatment with biological therapy or with an investigational product in the 4 weeks prior to initial IMP administration.
    10. Previous treatment with an aminobisphosphonate IV (e.g., ibandronate, pamidronate, zoledronate etc) within 4 weeks prior to initial IMP.
    11. Previous treatment of any systemic immunosuppressant within 2 weeks prior to initial IMP administration, with the exception of systemic corticosteroid use up to oral dose of 10 mg prednisolone daily (or equivalent for other steroids).
    12. Previous treatment with live or live attenuated vaccines within 2 weeks prior to initial IMP administration. Other (new) types of vaccines need to be evaluated as to their mode of action.
    13. Known non-CLL/MM/AML related pre-existing clinically relevant immunodeficiency disorders.
    14. Positive serological testing for Human Immunodeficiency Virus (HIV) antibody, hepatitis B surface antigen [HBsAg] and hepatitis B core antibody (anti-HBc) negative, and hepatitis C virus antibody. Patients who are positive for anti-HBc or hepatitis C antibody may be included if they have a negative PCR within 6 weeks prior to initial IMP administration. Those who are PCR positive will be excluded.
    15. Known allergies, hypersensitivity, or intolerance to the excipients of the IMP.
    16. Major surgery within 4 weeks of initial IMP administration or planned surgery during the time the patient is expected to participate in the trial.
    17. Known ongoing drug and alcohol abuse in the opinion of the investigator.
    1. Precedente trapianto di midollo osseo allogenico, se il paziente presenta malattia del trapianto contro l'ospite acuta o cronica con necessità di trattamento con > 10 mg di prednisone o di corticosteroidi equivalenti.
    2. Presenza concomitante di neoplasie maligne, ad eccezione del carcinoma in situ, del carcinoma basocellulare o del carcinoma cutaneo a cellule squamose. È consentita la partecipazione allo studio ai pazienti che non presentano alcuna evidenza di malattia da un altro carcinoma primario per un periodo pari o superiore a 2 anni. È consentita la partecipazione ai pazienti, affetti da cancro alla prostata localizzato non metastatico, che non necessita di un trattamento sistemico e per il quale non è previsto alcun trattamento locale.
    3. Condizione medica intercorrente non controllata o grave.
    4. Noto coinvolgimento del sistema nervoso centrale non controllato.
    5. Infezioni attive, non controllate o sospette.
    6. Anamnesi significativa di malattie renali, neurologiche, psichiatriche, polmonari, endocrinologiche, metaboliche, immunologiche, cardiovascolari o epatiche, che, secondo lo sperimentatore, potrebbero influire negativamente sulla partecipazione del paziente allo studio.
    7. Funzione cardiovascolare instabile, ossia: (a) ischemia sintomatica, (b) anomalie di conduzione non controllate clinicamente significative (pertanto si escludono i casi di tachicardia ventricolare trattata con agenti antiaritmici, mentre non si escludono i casi di blocco atrioventricolare di primo grado o blocco fascicolare anteriore sinistro/blocco di branca destra asintomatici), (c) insufficienza cardiaca congestizia di classe = 3 secondo la New York Heart Association, oppure (d) infarto del miocardio insorto negli ultimi 3 mesi.
    8. Precedente trattamento radioterapico, immunoterapico o chemioterapico, effettuato nelle 2 settimane precedenti alla somministrazione iniziale dell’IMP.
    9. Precedente trattamento con terapia biologica o con prodotto sperimentale, effettuato nelle 4 settimane precedenti alla somministrazione iniziale dell’IMP.
    10. Precedente trattamento con un aminobifosfonato, somministrato per e.v. (ad es. ibandronato, pamidronato, zoledronato, ecc.), effettuato nelle 4 settimane precedenti alla somministrazione iniziale dell’IMP.
    11. Precedente trattamento con un qualsiasi immunosoppressore sistemico, effettuato nelle 2 settimane precedenti alla somministrazione iniziale dell’IMP, ad eccezione dei trattamenti con corticosteroidi sistemici a una dose orale massima di 10 mg di prednisolone al giorno (oppure a una dose equivalente, nel caso in cui vengano utilizzati altri steroidi).
    12. Precedente trattamento con vaccini vivi oppure con vaccini vivi attenuati, effettuato nelle 2 settimane precedenti alla somministrazione iniziale dell’IMP. Gli altri (nuovi) tipi di vaccini devono essere valutati in base al loro meccanismo d’azione.
    13. Noti disturbi di immunodeficienza, clinicamente rilevanti, preesistenti e non correlati a LLC/MM/LMA.
    14. Test sierologico positivo per gli anticorpi contro il virus dell’immunodeficienza umana (HIV), positivo per l’antigene di superficie dell’epatite B (HBsAg) e negativo per gli anticorpi contro l’antigene core dell’epatite B (anti-HBc), e positivo per gli anticorpi contro il virus dell’epatite C. È possibile includere i pazienti che risultano positivi per l’anti-HBc o per gli anticorpi contro il virus dell’epatite C, se risultano negativi alla PCR nelle 6 settimane precedenti alla somministrazione iniziale dell’IMP. Saranno esclusi i pazienti la cui PRC risulta positiva.
    15. Nota allergia, ipersensibilità o intolleranza agli eccipienti dell’IMP.
    16. Intervento di chirurgia maggiore, effettuato nelle 4 settimane precedenti alla somministrazione iniziale dell’IMP, oppure intervento chirurgico previsto nel periodo in cui il paziente dovrebbe partecipare allo studio.
    17. Noto e presente abuso di alcolici e droghe, secondo il giudizio dello sperimentatore.
    E.5 End points
    E.5.1Primary end point(s)
    Part 1 Dose Escalation
    • Frequency and severity of Adverse Events using the Common Terminology Criteria and grading for Adverse Events (CTCAE version 5.0) and American Society for Transplantation and Cellular Therapy (ASTCT) grading for CRS.
    • Frequency and type of dose-limiting toxicity (DLT).
    Part 2 PoC
    • Antitumor Response:
    o For CLL patients: Response according to the most recent International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guideline (Appendix 6, Section 13.6.1).
    o For MM patients: Response according to the most recent International Myeloma Working Group (IMWG) criteria (Appendix 6, Section 13.6.3).
    o For AML patients: Response according to the most recent European LeukemiaNet (ELN) criteria (Appendix 6, Section 13.6.4).
    • Frequency and severity, including CTCAE and ASTCT grading, of AEs.
    Parte 1, Incremento progressivo della dose
    • Frequenza e gravità degli EA, sulla base della versione 5.0 dei CTCAE e sulla base della classificazione proposta dall’ASTCT per la CRS.
    • Frequenza e tipo di DLT.
    Parte 2, PoC
    • Risposta antitumorale:
    o Per i pazienti affetti da LLC: risposta valutata secondo le ultime linee guida dell’International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
    o Per i pazienti affetti da MM: risposta valutata secondo gli ultimi criteri dell’International Myeloma Working Group (IMWG).
    o Per i pazienti affetti da LMA: risposta valutata secondo gli ultimi criteri dell’European LeukemiaNet (ELN).
    • Frequenza e gravità degli EA, valutati anche secondo i CTCAE e la classificazione dell’ASTCT.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Part 1 AEs are monitored continuously from ICF signature until the FU visit. DLT is defined as an AE and is occurring during Cycle 1 (28 days). Part 2 Anti-tumor response will take place: 1) CLL: screening, Peripheral blood at predose of C1-6D1, CT-scan of neck/chest/abdomen in the C3-4th wk, Peripheral Blood MRD at predose of C4D1, BM biopsy in case of suspected remission based on CT analysis and blood evaluation and EoT. 2) MM: screening, Blood/24-h urine at predose of C1-6D1, BM biopsy in C3-4th wk and for confirmation of CR or at disease progression, CT-scan as clinically indicated to document progression and in the C3-4th wk, PE at predose of C1-6D1, and EoT. 3) AML: screening, Peripheral blood at predose of C1-6D1, BM biopsy in the C3-4th wk, MRD of C4D1 and EoT
    Parte 1 AE: monitorati continuamente dalla firma dell'ICF fino alla visita FU. La DLT è definita come un AE e si verifica durante il ciclo 1. Parte 2 La risposta antitumorale: CLL: screening, Sangue periferico alla pre-dose di C1-6D1, TC del collo/torace/addome nella C3-4a settimana, MRD del sangue periferico alla pre-dose di C4D1, BM biopsia in caso di sospetta remissione basata su analisi TC e valutazione del sangue ed EoT. MM: screening, sangue/urine delle 24h alla predose di C1-6D1, BM biopsia in C3- 4sett e per la conferma della CR o alla progressione della malattia, TC come clinicamente indicato per documentare la progressione e nel C3- 4sett, PE alla pre-dose di C1-6D1 ed EoT. AML: screening, sangue periferico alla predose di C1-6D1, BM biopsia nella C3-4a sett, MRD di C4D1 e EoT
    E.5.2Secondary end point(s)
    Part 1 Dose Escalation
    • For CLL patients: Response according to the most recent iwCLL guideline
    • For MM patients: Response according to the most recent IMWG criteria
    • For AML patients: Response according to the most recent most recent ELN criteria criteria
    Part 1 Dose Escalation and Part 2 PoC
    • Pharmacokinetic parameters.
    • Pharmacodynamic markers (binding of LAVA-051 to V¿9Vd2-T cells and CD1d positive tumor cells, frequency and activation status of V¿9Vd2-T cells and iNKT cells, induction of activation of V¿9Vd2-T cells ex vivo and general immune monitoring) and serum cytokines (IL-1ß, IL-2, IL-6, IL-8, TNF-a, IFN-¿) and CD1d and CD277 expression on tumor cells.
    • Presence or development of anti-LAVA-051 antibodies.
    Endpoint secondari:
    Parte 1, Incremento progressivo della dose
    • Per i pazienti affetti da LLC: risposta valutata secondo le ultime linee guida dell’iwCLL.
    • Per i pazienti affetti da MM: risposta valutata secondo gli ultimi criteri dell’IMWG.
    • Per i pazienti affetti da LMA: risposta valutata secondo gli ultimi criteri dell’ELN.
    Parte 1, Incremento progressivo della dose e Parte 2, PoC
    • Parametri farmacocinetici.
    • Marcatori farmacodinamici.
    • Presenza o sviluppo di anticorpi anti-LAVA-051.
    E.5.2.1Timepoint(s) of evaluation of this end point
    PK collection: SCR, C1D1 at predose, C1D1 1h after SoI, EoI, 15min after EoI, 30min after EoI, 1h, 1,5h, 2h, 3h, 4h, 6h, 8h and 12h after EoI, 24h, 36h, 48h, 72h and 96h after SoI; C1D2-D4-D6 at predose and EoI; C1D3 predose, EoI, 24h and 48h after SOI; C2D1 predose, EoI, 1h, 2h and 4h after EoI, 24h and 48h after SoI; C3-6D1 predose and EoI; EoT
    PD collection: SCR, C1D1 predose, 2h after EoI, 24h, 48h, 72h and 96h after SoI; C1D2-D4-D6 predose; C1D3 predose, 24h and 48h after SoI; C2D1 predose, 24h and 48h after SoI; C3-6D1 predose; EoT
    Lava antibodies collection: SCR, C1D1, C1D4, C2-6D1 and EoT.
    Raccolta PK: SCR, C1D1 alla predose, C1D1 1h dopo SoI, EoI, 15min dopo EoI, 30min dopo EoI, 1h, 1,5h, 2h, 3h, 4h, 6h, 8h e 12h dopo EoI, 24h, 36h, 48h, 72 ore e 96 ore dopo SoI; C1D2-D4-D6 a predose ed EoI; C1D3 predose, EoI, 24 ore e 48 ore dopo SOI; C2D1 predose, EoI, 1h, 2h e 4h dopo EoI, 24h e 48h dopo SoI; C3-6D1 predose ed EoI; EoT
    Raccolta PD: SCR, C1D1 predose, 2 ore dopo EoI, 24 ore, 48 ore, 72 ore e 96 ore dopo SoI; Predose di C1D2-D4-D6; Predose C1D3, 24 ore e 48 ore dopo SoI; C2D1 predose, 24 ore e 48 ore dopo SoI; Predose di C3-6D1; EoT
    Raccolta anticorpi Lava: SCR, C1D1, C1D4, C2-6D1 e EoT.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, immunogenicity, antitumor activity
    la tollerabilità, l’immunogenicità e l’attività antitumorale
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans Yes
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    di incremento progressivo della dose, di espansione della coorte
    Dose escalation and cohort expansion study
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA7
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The trial completion is defined as LPLV. For patients still on treatment beyond their maximum planned treatment duration follow up in the trial will end at the date of database lock of Part 2.
    Per ciascun paziente, lo studio si concluderà al completamento della fase di follow-up, tranne nei casi di decesso, ritiro del consenso o perdita al follow up.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 50
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 52
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 222
    F.4.2.2In the whole clinical trial 222
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the request of the treating physician and in consultation with the sponsor, continued access to IMP might be offered beyond the planned treatment duration of 24 weeks for individual patients with ongoing disease control provided that there is availability of IMP allocated to this trial
    Su richiesta del medico curante e in consultazione con lo sponsor, l'accesso continuo all'IMP potrebbe essere offerto oltre la durata prevista del trattamento di 24 settimane per i singoli pazienti con controllo della malattia in corso, a condizione che vi sia disponibilità di IMP assegnato a questo studio
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-10-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-11-10
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 12:43:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA